Abstract: Disclosed is a method for a communication device comprising a plurality of antenna elements arranged in an antenna array structure and configured to perform dynamic calibration of the antenna elements for beamforming. The method comprises performing interference level measurements and antenna calibration measurements during an antenna calibration opportunity, and adapting the antenna calibration measurements for one or more of the antenna elements based on the measured interference level. Corresponding apparatus, communication device and computer program product are also disclosed.

Abstract: The invention relates to an immediate release oral formulation of X842 comprising only limited amounts of surfactant. The invention also relates to the use of the oral formulation in the treatment of gastrointestinal inflammatory diseases or gastric acid related diseases, in particular erosive gastroesophageal reflux disease (eGERD).

Abstract: Disclosed is a method for a communication device comprising a plurality of antenna elements arranged in an antenna array structure and configured to perform dynamic calibration of the antenna elements for beamforming. The method comprises performing interference level measurements and antenna calibration measurements during an antenna calibration opportunity, and adapting the antenna calibration measurements for one or more of the antenna elements based on the measured interference level. Corresponding apparatus, communication device and computer program product are also disclosed.

Abstract: There is provided compounds of formula I (I) or pharmaceutically-acceptable salts thereof, wherein L, R1, R2, R3, R4 and n have meanings provided in the description, which compounds are useful in the treatment of cancers.

Abstract: There is provided compounds of formula I (I) or pharmaceutically-acceptable salts thereof, wherein L, R1, R2, R3, R4 and n have meanings provided in the description, which compounds are useful in the treatment of cancers.

Abstract: There is provided compounds of formula I (I) or pharmaceutically-acceptable salts thereof, wherein L, R1, R2, R3, R4 and n have meanings provided in the description, which compounds are useful in the treatment of cancers.

Abstract: The invention relates to a core drill with an end portion (3) and a drill bit portion (1-2). The end portion and the drill bit portion are joinable in a watertight fashion with a sealing element (11). The sealing element (11) is provided in a space between the end portion and the drill bit portion, such that it is being compressed in a sealing fashion when the end portion and the drill bit portion are joined. The end portion and the drill bit portion are locked together with a joining element (8, 10) which achieves this locking effect when moves in the radial direction of the core drill. When the joining element moves in this direction, the end portion and the drill bit portion move towards each other. Thus the sealing element is being compressed while concurrently the end portion and the drill bit portion are joined together. This is further achieved without the joining element having to extend in the axial direction of the core drill. Typically, the joining element (8, 10) is constituted by a set screw.

Abstract: The invention relates to a core drill with an end portion (3) and a drill bit portion (1-2). The end portion and the drill bit portion are joinable in a watertight fashion with a sealing element (11). The sealing element (11) is provided in a space between the end portion and the drill bit portion, such that it is being compressed in a sealing fashion when the end portion and the drill bit portion are joined. The end portion and the drill bit portion are locked together with a joining element (8, 10) which achieves this locking effect when moves in the radial direction of the core drill. When the joining element moves in this direction, the end portion and the drill bit portion move towards each other. Thus the sealing element is being compressed while concurrently the end portion and the drill bit portion are joined together. This is further achieved without the joining element having to extend in the axial direction of the core drill. Typically, the joining element (8, 10) is constituted by a set screw.

Abstract: The present invention relates to a filler comprising clay and cellulose derivative having a degree of substitution of net ionic groups up to about 0.65.

Abstract: The present invention relates to a filler comprising clay and cellulose derivative having a degree of substitution of net ionic groups up to about 0.65.

Abstract: The present invention relates to a filler comprising clay and cellulose derivative having a degree of substitution of net ionic groups up to about 0.65.

Abstract: The present invention relates to a filler comprising clay and cellulose derivative having a degree of substitution of net ionic groups up to about 0.65.

Abstract: The present invention relates to a filler comprising clay and cellulose derivative having a degree of substitution of net ionic groups up to about 0.65.

Abstract: The present invention provides a process for the preparation of substantially racemic 2-{[2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]-propanoic acid which comprises reacting 2-{[2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoic acid enriched in one enantiomer with a base in an inert solvent.

Abstract: The invention relates to heterocyclic derivatives of formula (I), Chemical formula should be inserted here. Please see paper copy wherein R1 is hydrogen or C1-3alkyl; R2 is selected from hydroxy, C1-5alkyl, carboxy, cyano, tetrazolyl, N—C1-5alkyltetrazolyl, oxazolyl, C1-5oxazolyl, isoxazolyl, C1-5 isoxazolyl, hydroxyC1-5alkyl, carboxy C1-5alkyl, C1-5alkoxyoxo C1-5alkyl, carbamoyl, C1-5alkylcarbamoyl, di(C1-5alkyl)carbamoyl, C1-5alkylcarbamoyl C1-4alkyl, hydroxy C1-5alkylcarbamoyl, C1-5alkoxy C1-5alkylcarbamoyl; —C1-5alkyl-Y1, —COOCHR17R18 and —CONR17R18; and R3 is hydrogen or halogen; or a pharmaceutically acceptable salt thereof, said compounds possess antithrombotic and anticoagulant properties and are accordingly useful in methods of treatment of humans or animals.

Abstract: The invention relates to compounds of formula (I), wherein R1 and R3 are independently selected from carbon and nitrogen; R2 is oxo or thioxo; n is 0, 1 or 2; each R10 is independently selected from hydrogen and C1-3alkyl; R4 and R5 are each selected from carbon and nitrogen, wherein at least one of R4 and R5 is nitrogen; R6 is hydrogen or oxo; R7 is an aliphatic, partially saturated or aromatic carbocyclic ring, said carbocyclic ring having 0, 1 or 2 hetero nitrogen; m is 0, 1 or 2; each R11 is independently selected from hydrogen, hydroxy, oxo, C1-5alkyl, carboxy, hydroxyC1-5alkyl, carboxyC1-5alkyl, C1-5alkoxy-oxoC1-5alkyl, carbamoyl, C1-5alkylcarbamoyl, di (C1-5 alkyl)carbamoyl, carbamoylC1-4alkyl,C1-5alkylcarbamoylC1-4alkyl, di(C1-5alkyl)carbamoylC1-4alkyl, hydroxyC1-5alkylcarbamoyl, C1-5 alkoxyC1-5alkylcarbamoyl, hydroxyC1-5alkylcarbamoylC1-4alkyl, C1-5alkoxyC1-5 alkylcarbamoylC1-4 alkyl, CONR80(CH2)xS(O)pR90, CONH(CH2)qNR100R100, —C1-5 alkyl-Y1, —COOCHR170R180 and —CON R170R180; R8 is a bond, C1-4alkyle

Abstract: The invention relates to compounds of formula (I), Chemical formula should be inserted here.

Abstract: The present invention relates to a method of treating polyaluminium compounds comprising contacting at least one polyaluminium compound in an aqueous solution with an anion exchange material capable of accepting anions or anionic groups and donating hydroxyl ions for a time necessary to obtain a polyaluminium compound having a higher molar ratio of hydroxide to aluminium than the polyaluminium compound had before contacting it with the anion exchange material.